• H F Gao, Y Liang, N N Zhou, D S Zhang, and H Y Wu.
• State Key Laboratory of Oncology in South China, Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
• Intern Med J. 2013 Jan 1; 43 (1): 73-6.

BackgroundChemotherapy-induced nausea and vomiting remain among the most feared adverse effects for cancer patients.AimThe aim of this study was to evaluate the efficacy and safety of a combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in patients receiving multiple-day cisplatin-based chemotherapy.MethodsForty-one solid cancer patients received aprepitant, palonosetron and dexamethasone during a 3-day cisplatin-based chemotherapy. Primary end-point was complete response in the overall phase (day 1 until 5 days after the end of chemotherapy).ResultsAprepitant in combination with palonosetron and dexamethasone was safe, with hiccups (31.7%), fatigue (17.1%), headache (14.6%) and constipation (12.2%) the most common treatment-related adverse events, mostly mild. Complete response was seen in 58.5% of patients in the overall phase. In 23 patients receiving aprepitant in combination with palonosetron and dexamethasone more than one cycle (range: 2-5 cycles), the cumulative emetic protection rate after five cycles was 0.82.ConclusionThis study shows aprepitant in combination with palonosetron and dexamethasone is safe and effectively controls chemotherapy-induced nausea and vomiting in patients undergoing 3-day cisplatin-based chemotherapy, moreover, the efficacy is maintained during multiple cycles.© 2011 The Authors; Internal Medicine Journal © 2011 Royal Australasian College of Physicians.

59 keywords...

hide…